Advertisement


Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

2024 ASCO Annual Meeting

Advertisement

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We designed the study back in 2012. It was a study of metformin, men with active surveillance for prostate cancer, and there was a lot of rationales as to why metformin would be useful in prostate cancer. There's laboratory studies that we've done speaking to the importance of metformin inhibiting mTOR as well as having epigenetic effects. There's data from other groups looking at the beneficial effect of metformin on the tumor microenvironment. There's epidemiological studies that suggest that diabetic men who take metformin do better for their prostate cancer treatment. There's combination studies that we've done demonstrating that, in some of the pivotal prostate cancer studies, the men who took metformin did better in the studies with abiraterone. So we put all those things together. We thought, well, metformin may be the perfect medication to give men undergoing active surveillance of prostate cancer. So from the period of 2013 to 2023, we randomised 400 men, approximately 204 on each arm to take metformin versus a matched placebo when they were undergoing active surveillance. And active surveillance is briefly, as per NCCN, very low to low risk criteria. Basically men with low volume Gleason 6 disease, and there's more details in the presentation, but those men were randomised over that period, and the endpoint was defined as either being therapeutic progression or pathological progression. The pathological progression was biopsies done at 18 and 36 months, and their therapeutic progression was any treatment for prostate cancer. And in brief, we found no difference between the arms, and in fact, there was a couple of concerning trends. One trend was that men who had a high BMI actually seemed to do worse on metformin for reasons we don't understand. And a priori, you would think those men would do better on metformin because they may lose weight, but that was not the case. And also there seemed to be a slight trend towards men progressing with higher Gleason scores who took metformin compared to those men who took placebo. This is a little bit worrying, and certainly we need to do more research to understand why this is the case. But this study was an academic study across 12 centers in Canada, funded through, essentially philanthropy, the Prostate Cancer Foundation, and the Canadian Cancer Association. So taken together, I think this has been a great academic effort. It will seed a lot of future research to understand the role of metformin and those types of drugs in men with and without diabetes for prostate cancer undergoing active surveillance.

Related Videos

Palliative Care

Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care

Joseph A. Greer, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses study findings showing the merits of delivering early palliative care via telehealth vs in person to patients with advanced lung cancer. Using telemedicine in this way may potentially improve access to and more broadly disseminate this evidence-based care model (LBA3).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.

Prostate Cancer

Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Colorectal Cancer

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).

Advertisement

Advertisement




Advertisement